Ori Biotech CEO Jason C. Foster to Discuss Key Developments During Company Presentation and Fireside Chat with Endpoints’ CEO Arsalan Arif.
LONDON, UK, January 13, 2025 – Oribiotech Ltd (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, announces today that CEO Jason C. Foster will present at Biotech Showcase and participate in a fireside chat hosted by Endpoints CEO Arsalan Arif during Endpoints @ #JPM in San Francisco, CA. Jason will discuss Ori Biotech’s innovations aimed at addressing key challenges in the access and manufacturing of cell and gene therapies.
Biotech Showcase
Presenter: Jason C. Foster
Date: Monday, January 13, 2025
Time: 10:00 – 10:15 AM (Pacific)
Location: Hilton San Francisco Union Square, San Francisco, CA
Fireside Chat at Endpoints @ #JPM
Topic: Unlocking the future of CGT manufacturing: In conversation with Ori Biotech CEO Jason C. Foster
Participants: Jason C. Foster and Arsalan Arif
Date: Tuesday, January 14, 2025
Time: 8:25 – 8:45 AM (Pacific)
Location: Marriott Marquis, 780 Mission St, San Francisco, CA
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year.
Endpoints at #JPM is the premier gathering for the biopharma industry as it kicks off the new year in San Francisco. This event brings together dealmakers, investors, and corporate leaders to shape the direction of the industry for the year ahead while taking stock of key financial and political developments. Endpoints Hub will provide live coverage from the heart of the action, offering exclusive insights and engaging in candid conversations with top industry speakers.
About Ori Biotech
Oribiotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori’s next-generation manufacturing platform, automates better biology, accelerates product development, and enables therapy developers to scale their products’ clinical and commercial impact. IRO® seamlessly transitions from R&D to GMP on one platform. The promise of the innovative Ori platform is to automate cell therapy manufacturing, increasing throughput, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics.
For news and updates, visit oribiotech.com/news-insights.
Media Relations
RXMD
Charlotte Wray
Tel: 646-247-3405
Email: media@oribiotech.com